DFTX EBITDA | Definium Therapeutics, Inc.

Definium Therapeutics, Inc. (DFTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$75.08M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$59.22M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$45.67M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$40.90M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$75.08M	(m)	(m)	(m)	(m)	-$52.78M*	(m)	$48.66M	(m)	(m)
2026-03-31	Reported	(m)	-$59.22M	(m)	(m)	(m)	(m)	-$42.63M	(m)	$41.48M	(m)	(m)
2025-09-30	Reported	(m)	-$45.67M	(m)	(m)	(m)	(m)	-$29.57M*	(m)	$30.98M	(m)	(m)
2025-06-30	Reported	(m)	-$40.90M	(m)	(m)	(m)	(m)	-$29.60M*	(m)	$29.81M	(m)	(m)
2025-03-31	Reported	(m)	-$32.16M	(m)	(m)	(m)	(m)	-$29.42M	(m)	$23.36M	(m)	(m)
2024-09-30	Reported	(m)	-$24.79M	(m)	(m)	(m)	(m)	-$17.19M*	(m)	$17.19M	(m)	(m)
2024-06-30	Reported	(m)	-$24.46M	(m)	(m)	(m)	(m)	-$19.99M*	(m)	$14.64M	(m)	(m)
2024-03-31	Reported	(m)	-$22.20M	(m)	(m)	(m)	(m)	-$16.60M	(m)	$11.71M	(m)	(m)
2023-09-30	Reported	(m)	-$21.62M	(m)	(m)	(m)	(m)	-$16.63M*	(m)	$13.20M	(m)	(m)
2023-06-30	Reported	(m)	-$29.18M	(m)	(m)	(m)	(m)	-$13.85M*	(m)	$14.78M	(m)	(m)
2023-03-31	Reported	(m)	-$20.86M	(m)	(m)	(m)	(m)	-$13.33M	(m)	$12.60M	(m)	(m)
2022-09-30	Reported	(m)	-$16.98M	(m)	(m)	(m)	(m)	-$9.30M*	(m)	$7.77M	(m)	$0.00
2022-06-30	Reported	(m)	-$16.94M	(m)	(m)	(m)	(m)	-$15.13M*	(m)	$9.33M	(m)	$0.00
2022-03-31	Reported	(m)	-$18.50M	(m)	(m)	(m)	(m)	-$12.87M	(m)	$10.24M	(m)	(m)
2021-09-30	Reported	(m)	-$17.23M	(m)	(m)	(m)	(m)	-$16.78M*	(m)	$9.02M	(m)	$0.00
2021-06-30	Reported	(m)	-$45.22M	(m)	(m)	(m)	(m)	-$11.17M*	(m)	$8.07M	(m)	$0.00
2021-03-31	Reported	(m)	-$13.85M	(m)	(m)	(m)	(m)	-$10.04M	(m)	$6.81M	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$166.31M	(m)	(m)	(m)	(m)	-$131.56M	(m)	$117.67M	(m)	$0.00
2024-12-31	Reported	(m)	-$103.92M	(m)	(m)	(m)	(m)	-$79.13M	(m)	$65.30M	(m)	(m)
2023-12-31	Reported	(m)	-$93.87M	(m)	(m)	(m)	(m)	-$64.36M	(m)	$52.12M	(m)	(m)
2022-12-31	Reported	(m)	-$66.33M	(m)	(m)	(m)	(m)	-$50.14M	(m)	$36.17M	(m)	(m)
2021-12-31	Reported	(m)	-$93.85M	(m)	(m)	(m)	(m)	-$45.82M	(m)	$34.79M	(m)	-$1.16M
2020-12-31	Reported	(m)	-$33.03M	(m)	(m)	(m)	(m)	-$23.60M	(m)	$18.63M	(m)	(m)

Stock Name	Country	Market Cap	PE Ratio
Cronos Group Inc. (CRON)		$1.223B
Tilray Brands, Inc. (TLRY)	United States	$0.554B	-5.97
Canopy Growth Corp (CGC)		$0.395B
USANA HEALTH SCIENCES INC (USNA)	United States	$0.264B	-17.90
Niagen Bioscience, Inc. (NAGE)	United States	$0.238B	15.72
FITLIFE BRANDS, INC. (FTLF)	United States	$0.087B	16.59
MANNATECH INC (MTEX)	United States	$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)	United States	$0.011B	-1.16
Synergy CHC Corp. (SNYR)	United States	$0.001B
Functional Brands Inc. (MEHA)	United States	$0.001B